Work

Cerebral myeloid sarcoma (Chloroma): Report of a rare entity

Year: 2025

Type: article

Abstract: INTRODUCTION AND IMPORTANCE: Myeloid sarcoma is a rare, malignant solid tumor composed of the progenitor cells of the myeloid lineage. Often associated with acute myeloid leukemia. Intracranial localization is very rare and diagnosis is confirmed by immunohistochemistry. The purpose of this case is to highlight the diagnostic and surgical treatment of a pathologically confirmed case of cerebral myeloid sarcoma. CASE PRESENTATION: We present the case of a 28-year-old Tunisian man who was diagnosed with AML in 2019, went into remission and was admitted to hospital with headaches and visual disturbances. Cranial MRI revealed an intra-axial parieto-occipital lesion on the left side. The patient underwent a successful surgical removal of the tumor. Immunohistochemistry confirms a cerebral myeloid sarcoma. CLINICAL DISCUSSION: Myeloid sarcoma is a rare condition. It is mainly found on skin and soft tissue. Intracranial localization is very rare. The clinical presentation of myeloid sarcoma varies depending on the location of the lesion. Histochemistry studies are essential for accurate diagnosis. There is no consensus on the treatment of myeloid sarcoma and different treatment strategies have been used. Surgery plays a key role in alleviating the symptoms of the mass effect, in confirming the diagnosis and in removing the major lesions before initiating systemic therapy. CONCLUSION: Cerebral myeloid sarcomas are uncommon. Intracranial mass should be strongly considered in acute myeloid leukemia patients. Conventional chemotherapy for AML is still the primary treatment for myeloid sarcomas, followed by surgery and possibly radiation.

Source: International Journal of Surgery Case Reports

DOI: 10.1016/j.ijscr.2025.111233

Authors: Mohamed Aziz Hermassi, Khalil Ghedira, Kais Bouzouita, Alia Zehani, Sofiene Bouali, Khansa Abderrahmen

Institution: National Institute of Neurology Mongi-Ben Hamida

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,090